"Esperion welcomes the opportunity to showcase additional data from our pivotal CLEAR Outcomes trial at the
CLEAR Outcomes Sub-group Poster Presentations
Title: | Characteristics and Outcomes for Statin-Intolerant Women Receiving Bempedoic Acid in the CLEAR Outcomes Trial |
Session: | 1213 |
Location: | Hall B4-5 |
Date & Time: | 4/6/24, 9:45 – |
Speaker: | |
Title: | Characteristics and Outcomes for Statin-Intolerant Hispanic/Latinx Patients Receiving Bempedoic Acid; Results from a CLEAR Outcomes Pre-Specified Sub-Analysis |
Session: | 1294 |
Location: | Hall B4-5 |
Date & Time: | 4/6/24,1:45 – |
Speaker: | |
Title: | Bempedoic Acid and Cardiovascular Disease Outcomes in Patients with Obesity: A CLEAR Outcomes Subset Analysis |
Session: Location: Date & Time: Speaker: | 1433 Hall B4-5 4/7/24, 1:15 – |
Moderated Presentation | |
Title: Session: Location: Date & Time: Speaker: | Impact of Payer Rejections and Out-Of-Pocket Costs on Patient Access to Bempedoic Acid Therapy 1092 4/7/24, 3:15 – |
Title: Location: Date & Time: Speaker: | A Next Step in Cardiovascular Disease Management Theatre #2 4/7/2024, |
At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases. The status quo is not meeting the health needs of millions of people with high cholesterol – that is why our team of passionate industry leaders is breaking through the barriers that prevent patients from reaching their goals. Providers are moving toward reducing LDL-cholesterol levels as low as possible, as soon as possible; we provide the next steps to help get patients there. Because when it comes to high cholesterol, getting to goal is not optional. It is our life’s work. For more information, visit esperion.com and esperionscience.com and follow us on X at twitter.com/EsperionInc.
CLEAR Cardiovascular Outcomes Trial
CLEAR Outcomes is part of the CLEAR clinical research program for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet. The CLEAR Program seeks to generate important clinical evidence on the safety and efficacy of bempedoic acid, a first in a class ATP citrate lyase inhibitor contained in NEXLETOL and NEXLIZET and its potential role in addressing additional critical unmet medical needs. More than 60,000 people will have participated in the program by the time of its completion. The CLEAR Program includes 5 label-enabling Phase III studies as well as other key Phase IV studies with the potential to reach more than 70 million people with or at risk for CVD based on elevated LDL-C.
Forward-Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding marketing strategy and commercialization plans, current and planned operational expenses, future operations, commercial products, clinical development, including the timing, designs and plans for the CLEAR Outcomes study and its results, plans for potential future product candidates, financial condition and outlook, including expected cash runway, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “suggest,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions. Any express or implied statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause Esperion’s actual results to differ significantly from those projected, including, without limitation, the net sales, profitability, and growth of Esperion’s commercial products, clinical activities and results, supply chain, commercial development and launch plans, the outcomes and anticipated benefits of legal proceedings and settlements, and the risks detailed in Esperion’s filings with the
Esperion Contact Information:
Investors:
investorrelations@esperion.com
(406) 539-1762
Media:
corporateteam@esperion.com
(616) 443-8438
Source:
2024 GlobeNewswire, Inc., source